{"description":"Adverse events (AEs) are reported by CTCAE version 4.0. Only participants that received PP-CSF during the first cycle of anti-cancer treatment were evaluated for adverse events. Population at risk for all-cause mortality includes all eligible and analyzable participants regardless of if they received PP-CSF.","eventGroups":[{"deathsNumAffected":44,"deathsNumAtRisk":707,"description":"CSF prescribing for patients taking anti-cancer drugs is based on existing automated system recommendations: CSF is recommended for drugs with high risk of FN; CSF is not recommended for drugs with low risk of FN.","id":"EG000","otherNumAffected":146,"otherNumAtRisk":456,"seriousNumAffected":3,"seriousNumAtRisk":456,"title":"Active Comparator: Clinic Group 1 (Clinics With Existing Automated System for CSF Prescribing)"},{"deathsNumAffected":42,"deathsNumAtRisk":644,"description":"CSF prescribing for patients taking anti-cancer drugs is based on existing clinical practice guidelines.","id":"EG001","otherNumAffected":123,"otherNumAtRisk":350,"seriousNumAffected":0,"seriousNumAtRisk":350,"title":"Active Comparator: Clinic Group 2 (Clinics With no Automated System for CSF Prescribing)"},{"deathsNumAffected":123,"deathsNumAtRisk":1281,"description":"CSF prescribing for patients taking anti-cancer drugs is based on automated system recommendations: CSF is recommended for drugs with intermediate or high risk of FN; CSF is not recommended for drugs with low risk of FN.","id":"EG002","otherNumAffected":243,"otherNumAtRisk":694,"seriousNumAffected":0,"seriousNumAtRisk":694,"title":"Experimental: Clinic Group 3 (Clinics With Automated System for CSF Prescribing)"},{"deathsNumAffected":68,"deathsNumAtRisk":973,"description":"CSF prescribing for patients taking anti-cancer drugs is based on automated system recommendations: CSF is recommended for drug with high risk of FN; CSF is not recommended for drugs with intermediate or low risk of FN.","id":"EG003","otherNumAffected":171,"otherNumAtRisk":448,"seriousNumAffected":1,"seriousNumAtRisk":448,"title":"Experimental: Clinic Group 4 (Clinics With Automated System for CSF Prescribing)"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":456},{"groupId":"EG001","numAffected":13,"numAtRisk":350},{"groupId":"EG002","numAffected":44,"numAtRisk":694},{"groupId":"EG003","numAffected":27,"numAtRisk":448}],"term":"Mucositis oral"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","stats":[{"groupId":"EG000","numAffected":51,"numAtRisk":456},{"groupId":"EG001","numAffected":44,"numAtRisk":350},{"groupId":"EG002","numAffected":81,"numAtRisk":694},{"groupId":"EG003","numAffected":76,"numAtRisk":448}],"term":"Arthralgia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","stats":[{"groupId":"EG000","numAffected":110,"numAtRisk":456},{"groupId":"EG001","numAffected":101,"numAtRisk":350},{"groupId":"EG002","numAffected":205,"numAtRisk":694},{"groupId":"EG003","numAffected":121,"numAtRisk":448}],"term":"Bone pain"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":456},{"groupId":"EG001","numAffected":2,"numAtRisk":350},{"groupId":"EG002","numAffected":24,"numAtRisk":694},{"groupId":"EG003","numAffected":23,"numAtRisk":448}],"term":"Myositis"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":456},{"groupId":"EG001","numAffected":0,"numAtRisk":350},{"groupId":"EG002","numAffected":0,"numAtRisk":694},{"groupId":"EG003","numAffected":1,"numAtRisk":448}],"term":"Sepsis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":456},{"groupId":"EG001","numAffected":0,"numAtRisk":350},{"groupId":"EG002","numAffected":0,"numAtRisk":694},{"groupId":"EG003","numAffected":0,"numAtRisk":448}],"term":"Neoplasms benign, malignant and unspecified - Other"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":456},{"groupId":"EG001","numAffected":0,"numAtRisk":350},{"groupId":"EG002","numAffected":0,"numAtRisk":694},{"groupId":"EG003","numAffected":0,"numAtRisk":448}],"term":"Respiratory failure"}],"timeFrame":"Adverse events were monitored/assessed through the end of first anti-cancer treatment cycle, an average of 21 days. While All-Cause Mortality was monitored/assessed for the entire duration participants are followed for the study, an average of 12 months."}